{"id":"ambisome-and-paromomycin","safety":{"commonSideEffects":[{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Ototoxicity"},{"rate":null,"effect":"Hepatotoxicity"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ambisome is a lipid formulation of amphotericin B that preferentially targets fungal ergosterol in cell membranes, causing membrane disruption and cell death while reducing toxicity to human cells. Paromomycin is an aminoglycoside that binds to the 30S ribosomal subunit of parasites, inhibiting protein synthesis. Together, this combination targets both fungal and parasitic pathogens, particularly in visceral leishmaniasis.","oneSentence":"Ambisome (liposomal amphotericin B) disrupts fungal cell membranes by binding ergosterol, while paromomycin is an aminoglycoside antibiotic that inhibits protein synthesis in parasites.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:01:05.045Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Visceral leishmaniasis (kala-azar)"},{"name":"Fungal infections in immunocompromised patients"}]},"trialDetails":[{"nctId":"NCT02366884","phase":"PHASE2","title":"Clinical Evaluation of a New Form of Cancer Therapy (Atavistic Chemotherapy) Based on the Principles of Atavistic Metamorphosis (2011)","status":"UNKNOWN","sponsor":"Dr. Frank Arguello Cancer Clinic","startDate":"2011-07-26","conditions":"Neoplasms","enrollment":250},{"nctId":"NCT03399955","phase":"PHASE2","title":"Short Course Regimens for Treatment of PKDL (Sudan)","status":"UNKNOWN","sponsor":"Drugs for Neglected Diseases","startDate":"2018-05-09","conditions":"PKDL - Post-Kala-Azar Dermal Leishmanioid","enrollment":110},{"nctId":"NCT01122771","phase":"PHASE3","title":"Phase III, Study of Three Short Course Combo (Ambisome®, Miltefosine, Paromomycin) Compared With AmBisome for the Treatment of VL in Bangladesh","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2010-05","conditions":"Visceral Leishmaniasis","enrollment":602},{"nctId":"NCT00216346","phase":"PHASE3","title":"Safety and Efficacy Study of Paromomycin to Treat Visceral Leishmaniasis","status":"COMPLETED","sponsor":"PATH","startDate":"2003-06","conditions":"Visceral Leishmaniasis","enrollment":667},{"nctId":"NCT00523965","phase":"PHASE3","title":"Combination Therapy in Indian Visceral Leishmaniasis","status":"COMPLETED","sponsor":"Banaras Hindu University","startDate":"2007-09","conditions":"Leishmaniasis, Visceral","enrollment":624},{"nctId":"NCT00696969","phase":"PHASE3","title":"Safety and Efficacy Study to Evaluate Different Combination Treatment Regimens for Visceral Leishmaniasis","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2008-06","conditions":"Visceral Leishmaniasis","enrollment":634}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":204,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Ambisome and Paromomycin","genericName":"Ambisome and Paromomycin","companyName":"Drugs for Neglected Diseases","companyId":"drugs-for-neglected-diseases","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ambisome is a small molecule that inhibits the bacterial 70S ribosome, classified as an INHIBITOR. It is used to treat various conditions, including Neoplasms, Visceral Leishmaniasis, Leishmaniasis, and PKDL - Post-Kala-Azar Dermal Leishmanioid, and is administered as an Anti-Protozoal Agent.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}